Table 2.
Univariate analyses of selected characteristics with survival among patients with oral squamous cell carcinoma.
| Characteristic | CD-I cohort (N = 118) |
CD-II cohort (N = 156) |
GZ cohort (N = 94) |
|||
|---|---|---|---|---|---|---|
| OS at five years |
P value⁎ |
OS at five years |
P value⁎ |
OS at five years |
P Value⁎ |
|
| (95% CI) | (95% CI) | (95% CI) | ||||
| Age | ||||||
| < 60 yr | 0.65 (0.51–0.76) | 0.510 | 0.47 (0.36–0.58) | 0.139 | 0.81 (0.66–0.90) | 0.057 |
| ≥ 60 yr | 0.56 (0.43–0.68) | 0.56 (0.45–0.66) | 0.61 (0.46–0.73) | |||
| Sex | ||||||
| Male | 0.58 (0.46–0.67) | 0.327 | 0.54 (0.45–0.63) | 0.422 | 0.67 (0.52–0.78) | 0.352 |
| Female | 0.68 (0.50–0.80) | 0.45 (0.30–0.59) | 0.74 (0.58–0.85) | |||
| Smoking history | ||||||
| Never | 0.75 (0.63–0.84) | < 0.001 | 0.58 (0.46–0.68) | 0.108 | 0.75 (0.60–0.85) | 0.097 |
| Ever | 0.43 (0.30–0.56) | 0.46 (0.35–0.57) | 0.64 (0.48–0.76) | |||
| Drinking history | ||||||
| Never | 0.69 (0.56–0.79) | 0.037 | 0.65 (0.54–0.75) | < 0.001 | 0.78 (0.65–0.87) | 0.027 |
| Ever | 0.52 (0.38–0.64) | 0.39 (0.28–0.49) | 0.58 (0.41–0.72) | |||
| Cell differentiation | ||||||
| High | 0.70 (0.58–0.79) | 0.003 | 0.58 (0.48–0.66) | 0.020 | 0.75 (0.63–0.83) | 0.042 |
| Moderate or Low | 0.44 (0.29–0.58) | 0.40 (0.27–0.53) | 0.55 (0.32–0.72) | |||
| Primary site | ||||||
| Ventral tongue/floor of mouth | 0.59 (0.44–0.72) | 0.814 | 0.56 (0.44–0.67) | 0.477 | 0.72 (0.58–0.82) | 0.265 |
| Buccal mucosa | 0.67 (0.40–0.83) | 0.44 (0.25–0.62) | 0.86 (0.33–0.98) | |||
| Gingiva | 0.67 (0.38–0.85) | 0.43 (0.23–0.62) | 0.50 (0.25–0.71) | |||
| Othersa | 0.57 (0.39–0.71) | 0.54 (0.37–0.69) | 0.60 (0.13–0.88) | |||
| Tumor stage | ||||||
| T1 or T2 | 0.66 (0.55–0.74) | 0.003 | 0.56 (0.45–0.66) | 0.183 | 0.76 (0.64–0.85) | 0.076 |
| T3 or T4 | 0.33 (0.15–0.53) | 0.47 (0.36–0.58) | 0.53 (0.32–0.71) | |||
| Nodal stage | ||||||
| N0 | 0.72 (0.60–0.80) | < 0.001 | 0.61 (0.51–0.70) | < 0.001 | 0.78 (0.67–0.86) | < 0.001 |
| N1-N3 | 0.36 (0.21–0.51) | 0.31 (0.19–0.44) | 0.43 (0.23–0.62) | |||
| Clinical TNM stage | ||||||
| I or II | 0.76 (0.65–0.85) | < 0.001 | 0.61 (0.48–0.71) | 0.024 | 0.79 (0.66–0.88) | 0.041 |
| III or IV | 0.36 (0.22–0.49) | 0.46 (0.35–0.55) | 0.57 (0.40–0.71) | |||
| Surgical method | ||||||
| Local | 0.61 (0.46–0.73) | 0.878 | 0.60 (0.46–0.72) | 0.116 | 0.78 (0.51–0.91) | 0.318 |
| Unilateral or bilateral or other | 0.60 (0.48–0.71) | 0.48 (0.38–0.57) | 0.68 (0.56–0.77) | |||
| Radiotherapy | ||||||
| Yes | 0.78 (0.36–0.94) | 0.347 | 0.43 (0.25–0.60) | 0.218 | 1.00 (1.00–1.00) | 0.008 |
| No | 0.59 (0.48–0.68) | 0.54 (0.45–0.62) | 0.64 (0.52–0.74) | |||
| Chemotherapy | ||||||
| Yes | 0.74 (0.61–0.83) | 0.002 | 0.57 (0.46–0.67) | 0.204 | 0.75 (0.58–0.86) | 0.147 |
| No | 0.44 (0.31–0.57) | 0.46 (0.34–0.57) | 0.65 (0.51–0.77) | |||
| Radiotherapy or chemotherapy | ||||||
| Yes | 0.75 (0.62–0.83) | < 0.001 | 0.58 (0.47–0.67) | 0.097 | 0.78 (0.63–0.88) | 0.015 |
| No | 0.42 (0.28–0.55) | 0.43 (0.31–0.55) | 0.60 (0.44–0.73) | |||
| PA28γ | ||||||
| Low expression | 0.84 (0.71–0.91) | < 0.001 | 0.67 (0.56–0.75) | < 0.001 | 0.89 (0.74–0.96) | < 0.001 |
| High expression | 0.40 (0.28–0.52) | 0.28 (0.18–0.40) | 0.57 (0.43–0.69) | |||
Abbreviations: OS, Overall Survival; CD, Chengdu; GZ, Guangzhou.
⁎
P value was determined using the log-rank test.
a
Others included hard palate, mandibular and lip mucosa.